<DOC>
	<DOCNO>NCT01728935</DOCNO>
	<brief_summary>Tenofovir ( TDF ) demonstrate potency antiviral hepatitis B virus ( HBV ) various multiple-centre trial , case resistance encounter . However , efficacy resistance profile Asian population , constitute majority chronic hepatitis B ( CHB ) patient , unknown . Compared nucleoside analogue , TDF associate relatively high rate hepatitis B surface antigen ( HBsAg ) seroclearance . It would interested see could reproduce . The investigator plan report serologic virologic result 140 nucleoside analogue-experienced patient commence TDF .</brief_summary>
	<brief_title>Tenofovir Asian Chronic Hepatitis B Patients</brief_title>
	<detailed_description>Recent multi-center trial show tenofovir disoprovil fumarate ( TDF ) demonstrate potent antiviral efficacy nucleoside-naive -experienced chronic hepatitis B ( CHB ) patient . At present , identifiable amino acid substitution associate resistance TDF . Since TDF adefovir ( ADV ) , another license drug CHB , belong molecular group , acyclic phosphonate , various study investigate efficacy TDF ADV-resistant patient . The efficacy tenofovir group patient conflict . While several study show TDF achieve similar viral suppression compare CHB patient without ADV-resistance , another study find patient signature ADV mutation rtA181V/T /or rtN236T respond suboptimally TDF . For published study , number patient document genotypic resistance adefovir actually small ( n = 17-40 ) , therefore , study area require . Another interesting point note relatively high rate hepatitis B surface antigen ( HBsAg ) seroclearance find patient take TDF . The cumulative rate HBsAg seroclearance hepatitis B e antigen ( HBeAg ) -positive 10 % 4 year . However , study find HBeAg-negative patient achieve HBsAg seroclearance . In addition , study TDF mainly perform Caucasian patient , majority genotypes A D. A preliminary study perform Asian patient , predominantly genotypes B C , discover case HBsAg seroclearance . Given majority CHB population find Asia , study need clarify HBsAg seroclearance nucleoside / nucleotide analogues potentially achievable use TDF .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . HBsAgpositivity least 6 month presentation 2 . Commenced tenofovir chronic hepatitis B 3 . Exposure nucleoside analogue start TDF 1 . Concomitant liver disease include chronic hepatitis C and/ D infection , Wilson 's disease , autoimmune hepatitis , primary biliary cirrhosis primary sclerosing cholangitis . 2 . Significant alcohol intake ( &gt; 20 gram per day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>HBV</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>HBV DNA</keyword>
	<keyword>HBsAg</keyword>
	<keyword>Resistance</keyword>
</DOC>